GSK Beats Q3 Estimates but Vaccine Slump and £1B Restructuring Charge Drag Shares Down 3.5%
GSK is trading near its 52-week low of $42.885 (14% above the low).
Summary
GSK beat on both lines: adjusted EPS of $1.47 versus $1.40 consensus and revenue of $11.948 billion, up 4%, versus $11.80 billion expected. The mix is the problem. Specialty medicines rose 14% to 3.87 billion pounds, led by HIV up 9%, but vaccines fell 4% to 2.583 billion pounds as Arexvy dropped 22% and Shingrix slipped 6% on weaker China sales. Management reaffirmed 2026 guidance but skewed it: sales and core operating profit growth now expected in the upper halves of their ranges, while core EPS growth lands in the lower half. The Accelerate Growth restructuring is running ahead of schedule and charges are now seen at up to £1 billion in 2026, with a £0.3 billion hit already in the quarter. Shares are down 3.52% at $49.15 — the market is paying for the vaccine weakness and the higher charge, not the headline beat.
At the time of this announcement, GSK was trading at $48.75 on NYSE in the Life Sciences sector, with a market capitalization of approximately $102.5B. The 52-week trading range was $42.89 to $61.70. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Benzinga.